ASCO 2022 | PROpel: analysis of drug interactions between olaparib + abiraterone as 1L therapy in mCRPC

Andrew J. Armstrong, MD, Duke Cancer Center, Durham, NC, discusses the pharmacokinetics (PK) data from the PROpel trial (NCT03732820), a double-blind, Phase III trial of abiraterone and olaparib vs abiraterone and placebo as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Combination treatment of olaparib and abiraterone in patients with mCRPC had no clinically significant effect on the PK profiles of either drug.This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.